Medicxi Ventures Management’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Medicxi Ventures Management’s Portfolio CMPI Stock Details CMPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,501,716	Closed	-$12.5M	–	7
2022 Q1	$4.79M	Hold	1,501,716	–	–	1.3%	6
2021 Q4	$4.31M	Hold	1,501,716	–	–	1.08%	6
2021 Q3	$5.96M	Hold	1,501,716	–	–	1.3%	5
2021 Q2	$8.95M	Hold	1,501,716	–	–	1.6%	5
2021 Q1	$18.2M	Hold	1,501,716	–	–	10.62%	4
2020 Q4	$21.9M	Hold	1,501,716	–	–	12.73%	4
2020 Q3	$17.3M	Buy	+1,501,716	New	+$19.2M	8.25%	4

Medicxi Ventures Management's CMPI Position: Q2 2022 in Review

Medicxi Ventures Management sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2022, closing a stake of 1,501,716 shares — an estimated $12.5M sold.

Medicxi Ventures Management first reported a position in CMPI in Q3 2020 and held it in 7 quarters. The position peaked at $21.9M in Q4 2020. 0 funds tracked by Wall St. Rank hold CMPI as of Q2 2022.

Medicxi Ventures Management reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Medicxi Ventures Management sold 1,501,716 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $12.5M.
Medicxi Ventures Management first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
Medicxi Ventures Management's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $21.9M in Q4 2020.
0 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Medicxi Ventures Management's 13F filing for Q2 2022, filed 3 Aug 2022.